\r\n The old traders’ adage “better to travel than arrive” has been true in 2017. Last year wa...
\r\n President Donald Trump signed on 28 March 2017 an executive order to unravel former President B...
\r\n According to some scientists, the fingerprint of human-caused climate change has been found on ...
\r\n Australia’s federal government has announced it will ratify and implement the OPCAT Treaty, O...
\r\n Nurses and teachers are among those bearing the brunt of a debt crisis rooted in the mistaken b...

Follow us



The multinational pharmaceutical companies (MNCs),which have so far lagged the domestic market growth, are now becoming increasingly aggressive in the Indian market as part of their focus on emerging markets. In the past, most of MNCs players had maintained a subdued profile in India owing to limitation on launch of patented products, limited marketing and distribution bandwidth and relatively small scale offered by the Indian market.

However, with the implementation of the product patent regime and strong growth prospects, the landscape for MNCs pharmaceutical companies is gradually changing. Series of major acquisitions, steady growth in new product introductions (especially in the branded segment with steep pricing difference to global prices) and expansion in field force clearly indicates their renewed interest in the Indian market.

A new study reports that the MNCs are implementing strategies to allow India's large patient population (not only rich people) the access to essential drugs. This aim is hard to reach due to the several poverty rate and the country's large population. In 2010, India counted 1.2 billion people (the total of the combined populations of North America, Europe and Japan) and it is expected to increase by 2030.

Strategies such as differential pricing, providing lower-cost, high quality branded generics are oriented to fill the gaps in patient access. Partnering with local companies can distribute drugs at lower prices, tiered pricing based on disease prevalence and gross national income.

India is one of the countries which fail to protect and enforce intellectual property. In fact, Pharmaceutical Research and Manufacturers of America requested that the Office of the United States Trade Representative designate India as a Priority Foreign Country.

The gLAWcal Team

Tuesday, May 13, 2014

(Source: The Pharma Letter)

This news has been realized by gLAWcal—Global Law Initiatives for Sustainable Development in collaboration with the University Institute of European Studies (IUSE) in Turin, Italy and the University of Piemonte Orientale, Novara, Italy which are both beneficiaries of the European Union Research Executive Agency IRSES Project “Liberalism in Between Europe And China” (LIBEAC) coordinated by Aix-Marseille University (CEPERC). This work has been realized in the framework of Workpackages 4, coordinated by University Institute of European Studies (IUSE) in Turin, Italy.